JP2017527602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527602A5 JP2017527602A5 JP2017515074A JP2017515074A JP2017527602A5 JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5 JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidine
- piperidin
- carboxylic acid
- pyridin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020035272A JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052537P | 2014-09-19 | 2014-09-19 | |
| US62/052,537 | 2014-09-19 | ||
| PCT/IB2015/057219 WO2016042536A1 (en) | 2014-09-19 | 2015-09-18 | Novel soluble guanylate cyclase activators and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035272A Division JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527602A JP2017527602A (ja) | 2017-09-21 |
| JP2017527602A5 true JP2017527602A5 (https=) | 2018-10-25 |
| JP6678656B2 JP6678656B2 (ja) | 2020-04-08 |
Family
ID=54238488
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515074A Active JP6678656B2 (ja) | 2014-09-19 | 2015-09-18 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
| JP2020035272A Active JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
| JP2021109106A Pending JP2021155450A (ja) | 2014-09-19 | 2021-06-30 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035272A Active JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
| JP2021109106A Pending JP2021155450A (ja) | 2014-09-19 | 2021-06-30 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9938260B2 (https=) |
| EP (1) | EP3194384A1 (https=) |
| JP (3) | JP6678656B2 (https=) |
| KR (1) | KR20170054508A (https=) |
| CN (1) | CN106687456B (https=) |
| AU (1) | AU2015319724B2 (https=) |
| BR (1) | BR112017005660A2 (https=) |
| CA (1) | CA2961745A1 (https=) |
| CL (1) | CL2017000640A1 (https=) |
| CO (1) | CO2017002506A2 (https=) |
| CR (1) | CR20170102A (https=) |
| DO (1) | DOP2017000073A (https=) |
| EA (1) | EA033697B1 (https=) |
| IL (1) | IL251094A0 (https=) |
| MA (1) | MA40583A (https=) |
| MX (1) | MX2017003621A (https=) |
| PE (1) | PE20170937A1 (https=) |
| PH (1) | PH12017500481A1 (https=) |
| SG (1) | SG11201701915TA (https=) |
| WO (1) | WO2016042536A1 (https=) |
| ZA (1) | ZA201701835B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102352388B1 (ko) | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물 |
| MA39484A (fr) | 2014-09-19 | 2016-03-24 | Bayer Pharma AG | Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1 |
| EA033697B1 (ru) * | 2014-09-19 | 2019-11-18 | Glaxosmithkline Ip Dev Ltd | Активаторы растворимой гуанилатциклазы и их применение |
| CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| JP7314173B2 (ja) | 2018-04-30 | 2023-07-25 | バイエル アクチェンゲゼルシャフト | 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602143A (en) | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| TWI409081B (zh) * | 2006-11-09 | 2013-09-21 | Alcon Res Ltd | 用於藥物輸送之水不溶性聚合物基質 |
| PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
| DE102009012314A1 (de) * | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| JP5636296B2 (ja) | 2011-01-20 | 2014-12-03 | 公益財団法人微生物化学研究会 | 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体 |
| EA033697B1 (ru) * | 2014-09-19 | 2019-11-18 | Glaxosmithkline Ip Dev Ltd | Активаторы растворимой гуанилатциклазы и их применение |
-
2015
- 2015-09-18 EA EA201790655A patent/EA033697B1/ru not_active IP Right Cessation
- 2015-09-18 WO PCT/IB2015/057219 patent/WO2016042536A1/en not_active Ceased
- 2015-09-18 KR KR1020177010181A patent/KR20170054508A/ko not_active Ceased
- 2015-09-18 CA CA2961745A patent/CA2961745A1/en not_active Abandoned
- 2015-09-18 MA MA040583A patent/MA40583A/fr unknown
- 2015-09-18 JP JP2017515074A patent/JP6678656B2/ja active Active
- 2015-09-18 EP EP15772026.9A patent/EP3194384A1/en not_active Withdrawn
- 2015-09-18 BR BR112017005660A patent/BR112017005660A2/pt not_active Application Discontinuation
- 2015-09-18 SG SG11201701915TA patent/SG11201701915TA/en unknown
- 2015-09-18 CR CR20170102A patent/CR20170102A/es unknown
- 2015-09-18 US US15/509,895 patent/US9938260B2/en active Active
- 2015-09-18 MX MX2017003621A patent/MX2017003621A/es unknown
- 2015-09-18 AU AU2015319724A patent/AU2015319724B2/en active Active
- 2015-09-18 CN CN201580050717.XA patent/CN106687456B/zh active Active
- 2015-09-18 PE PE2017000478A patent/PE20170937A1/es unknown
-
2017
- 2017-03-12 IL IL251094A patent/IL251094A0/en unknown
- 2017-03-14 ZA ZA2017/01835A patent/ZA201701835B/en unknown
- 2017-03-14 PH PH12017500481A patent/PH12017500481A1/en unknown
- 2017-03-16 DO DO2017000073A patent/DOP2017000073A/es unknown
- 2017-03-16 CL CL2017000640A patent/CL2017000640A1/es unknown
- 2017-03-16 CO CONC2017/0002506A patent/CO2017002506A2/es unknown
-
2018
- 2018-03-05 US US15/911,797 patent/US10472350B2/en active Active
-
2020
- 2020-03-02 JP JP2020035272A patent/JP6908747B2/ja active Active
-
2021
- 2021-06-30 JP JP2021109106A patent/JP2021155450A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527602A5 (https=) | ||
| JP2016525076A5 (https=) | ||
| MX2025010774A (es) | Formas en estado solido | |
| JP2019528307A5 (https=) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2019505594A5 (https=) | ||
| JP2018519323A5 (https=) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| JP2017502940A5 (https=) | ||
| JP2003521537A5 (https=) | ||
| JP2016520131A5 (https=) | ||
| JP2019535672A5 (https=) | ||
| JP2013510125A5 (https=) | ||
| JP2017528487A5 (https=) | ||
| JP2016538313A5 (https=) | ||
| JP2016514719A5 (https=) | ||
| JP2017504611A5 (https=) | ||
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| NZ592297A (en) | 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents | |
| JP2014511891A5 (https=) | ||
| JP2013540823A5 (https=) | ||
| JP2009515814A5 (https=) | ||
| FI3555076T3 (fi) | Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja | |
| JP2015514806A5 (https=) | ||
| JP2004511469A5 (https=) |